Market Overview

Wedbush Maintains Outperform on Sarepta Therapeutics, Inc., Lowers PT to $60.00

Get News First. Profit Faster

upsell-button
With Benzinga Professional get unlimited access to ALL content! PLUS:
  • REALTIME NEWSFEED
  • REALTIME AUDIO NEWS
  • FULL CALENDAR SUITE
  • CHAT WITH OUR NEWS DESK

Latest Ratings for SRPT

DateFirmActionFromTo
Oct 2014BairdDowngradesOutperformNeutral
Oct 2014Stifel NicolausDowngradesBuyHold
Oct 2014JMP SecuritiesDowngradesMarket OutperformMarket Perform

View More Analyst Ratings for SRPT
View the Latest Analyst Ratings

Posted-In: News Price Target Analyst Ratings

 

Related Articles (SRPT)

Around the Web, We're Loving...

Get Benzinga's Newsletters